Although this overall improvement in survival might encourage a shift toward more liberal admission policies and aggressive treatment strategies, most intensivists have witnessed prolonged ICU stays of cancer patients who had unfavorable outcomes and have been reluctant to accept data collected in other medical centers as representative of the intensivists' own daily practice. Many epidemiological studies of cancer patients admitted to the ICU have been conducted either in university cancer referral centers or in exclusively oncological ICUs. 10, [15] [16] [17] Therefore, extrapolation of findings to general ICUs and hospitals is not straightforward, and each ICU should ideally develop its own triage criteria and periodically evaluate and review its performance. 14 Nowadays, shortages of available ICU beds are common, and intensivists prioritize admissions of critically ill patients. Practical and widely available screening tools may help in informing patients and patients' families about prognosis. Most scoring systems currently in use, such as the Acute Physiology and Chronic Health Evaluation (APACHE) II, 18 the Simplified Acute Physiology Score (SAPS II), 19 and the Sequential Organ Failure Assessment (SOFA), 20 were constructed and validated in general ICU populations, not in specific groups of patients, such as patients with underlying malignant neoplasms. The results of evaluations of these general prognostic models in cohorts of cancer patients have been either positive 17, [21] [22] [23] [24] [25] [26] [27] or negative. 16, [27] [28] [29] Taking these factors into account, we conducted this study to determine the characteristics and outcomes of cancer patients admitted to the ICU, identify risk factors associated with mortality, evaluate and compare the effectiveness of established general scoring systems (APACHE II, SAPS II, and SOFA) in the prediction of ICU mortality of cancer patients, and determine if the addition of other predictors of mortality to these established scoring systems could improve their performance.
Methods

Study Population and Setting
This study was conducted between January 1, 2005, and December 31, 2007 , in the 21-bed, mixed medical-surgical "closed" ICU at "Attiko" Hospital,
I
ntensivists have traditionally viewed cancer patients as poor candidates for admission to the intensive care unit (ICU). 1 Advances in early detection and treatment 2 have led to improvements in long-term survival in many types of cancer. These improvements come at the cost of an escalating number of patients who experience cancer-related complications and/or treatment-related adverse events 3 and thus need specialized intensive care. Fortunately, since the 1980s, the mortality rate of critically ill cancer patients admitted to the ICU has decreased, 4 including mortality among those who are recipients of hematopoietic stem cell transplants 5 and those who require life-sustaining therapies for the management of acute respiratory failure, [6] [7] [8] acute renal failure, 9 or septic shock. 10, 11 This decrease in mortality has been attributed to a better understanding of the pathophysiology of certain cancer-related complications and the development of effective targeted treatments (eg, rasburicase for tumor lysis syndrome definitions and criteria. 31, 32 Use of norepinephrine, dopamine, dobutamine, and/or adrenaline for any time, as indicated in a patient's chart, was defined as use of vasopressors. Other information recorded was the type of ventilatory support (conventional vs noninvasive mechanical ventilation), irrespective of its duration, and the institution of renal replacement therapy. The need for mechanical ventilation, vasopressors, and renal replacement therapy; development of leukopenia, anemia, thrombocytopenia, renal dysfunction, hepatic dysfunction, and ICU-acquired infections; and the administration of chemotherapy were recorded for each patient for the entire duration of the patient's ICU stay.
The primary outcome of interest was the ICU mortality; lengths of ICU stay and mechanical ventilation were also recorded.
Statistical Analysis
Standard descriptive statistics were used to describe the study population. Continuous variables were reported as means and standard deviations or as medians (25%-75% interquartile range [IQR]), and categorical variables were reported as percentages. Patients' characteristics were compared by using the χ 2 or the Fisher exact test (where applicable) for categorical variables and by using a t test (for normally distributed data) or the nonparametric Wilcoxon test or the Kruskal-Wallis test (for nonnormally distributed data) for continuous variables.
In order to investigate the association between patients' characteristics and ICU mortality, univariate analyses were done to detect a significant influence of each variable on ICU mortality. Clinically relevant variables yielding P < .10 in the univariate analyses that would also be easily accessible on admission were entered into multiple logistic regression models with ICU mortality as the outcome variable of interest. Three logistic regression models were used; because of collinearity, only 1 of the 3 scoring systems (APACHE II, SAPS II, SOFA) was included each time in the multivariate analysis, and parameters already encompassed by the scoring systems (eg, age and leukopenia in the APACHE II score) were not entered simultaneously in the analysis.
The area under the receiver operating characteristic curve (AUROC) was used to assess the capability of each prognostic model for discriminating between survivors and nonsurvivors (discrimination) 33 by plotting the sensitivities for all individual cutoff values vs the corresponding (100 -specificity) values for the same cutoffs. AUROC values higher than 0.8 are generally described as good, values School of Medicine, University of Athens, Athens, Greece, a tertiary, university hospital with 700 beds, and in a 6-bed, mixed medical-surgical closed ICU at "Metaxa" Hospital, Pireas, Greece, a general hospital with 350 beds. The study was approved by the institutional review board of each facility; informed consent was waived because the study was observational and did not interfere with patients' care. During the study period, every adult patient (>18 years old) with a pathologically proven cancer who required ICU admission was evaluated. If a patient had multiple admissions, only the first admission was considered. Patients who had been admitted for routine postoperative monitoring were excluded.
Data Collection
The following data were collected at the time of admission to the ICU: age, sex, source of admission (internal medicine vs surgery department), main reason for admission, duration of hospital stay before ICU admission, and previous comorbid conditions. The histological type of the solid tumor or the hematologic cancer, the cancer status (new diagnosis vs recurrent disease and locoregional vs metastatic disease), the administration of chemotherapy in the month before ICU admission, and the patient's preadmission performance status as determined by using the Eastern Cooperative Oncology Group scale 30 were also recorded. During the first 24 hours of the ICU stay, the "worst" or most critical physiological and laboratory parameters were measured to calculate the APACHE II, SOFA, and SAPS II scores as described in the original publications about the scoring systems. [18] [19] [20] Leukopenia was defined as white blood cell count less than 1000/µL, anemia as hemoglobin level less than 10 g/dL, thrombocytopenia as platelet count less than 100 000/µL, hepatic dysfunction as bilirubin level greater than 2 mg/dL (to convert to micromoles per liter, multiply by 17.104) and/or transaminases more than 3 times the upper level of normal values, and renal dysfunction as creatinine level greater than 1.5 mg/dL (to convert to micromoles per liter, multiply by 88.4). Serum glucose and lactate levels at admission were also recorded. In addition, patients were monitored for sepsis and infection according to standard ICUs in both a tertiary university hospital and a general hospital were used.
Every adult with a proven cancer requiring ICU admission was evaluated.
between 0.6 and 0.8 are considered moderate, and values lower than 0.6 are poor. 34 AUROCs were compared by using the Hanley-McNeil method. 35 P values less than .05 were considered significant.
The Hosmer-Lemeshow goodness-of-fit test was used to evaluate the agreement between the observed and the expected number of patients who did or did not die in the hospital across all the strata of probabilities of death (calibration). 36 With this test, a P value greater than .05 indicates a good fit for the model. Calibration curves were constructed by plotting predicted mortality rates stratified by 10% intervals of mortality risk against observed mortality rates. Standardized mortality ratios (SMRs) with 95% confidence intervals (95% CIs) were calculated for each model by dividing observed mortality rates by predicted rates. Therefore, an SMR greater than 1.0 implies that a prognostic score is an underestimate of the observed mortality, whereas an SMR less than 1.0 is an overestimate of the observed mortality. 34 Statistical analyses were carried out by using SPSS, version 10.0 (SPSS Inc, Chicago, Illinois), and MedCalc software, version 6.16 (MedCalc, Mariakerke, Belgium). Tables 1 and 2 give the main demographic and clinical characteristics of the 126 patients in the study and the underlying cancers, respectively. Table 3 is a summary of severity-of-illness characteristics of the study cohort on the day of ICU admission and during the ICU stay. ICU mortality was 46.8% (59 of 126 patients). Median durations were 6 days (IQR, 4-16) for ICU stay and 5 days (IQR, 1-13) for mechanical ventilation. Table 4 displays the results of the univariate analysis of variables related to ICU mortality. Age and sex did not seem to have an effect, whereas the source of admission and the number of hospital days before ICU admission did. Approximately 80% of patients admitted from medical departments vs 20% from surgical departments did not survive. Among cancer-related parameters, hematologic cancers, a performance status of 3 to 4 (bedridden), and chemotherapy in the previous month were unfavorably associated with ICU survival.
Results
Patients' Characteristics, Resource Utilization, and Outcome Analysis
Univariate Analysis
As expected, nonsurvivors had higher APACHE II, SOFA, and SAPS II scores. Other predictors of ICU mortality available at admission were the need www.ajcconline.org Tables 5 and 6 , and Figures 1 and 2 .
Performance of the Prognostic Models
The individual performances of each of the 3 models derived from the multivariate analyses and of the 3 general prognostic models are presented in Table 6 .
The AUROCs were 0.90 for APACHE II, 0.83 for SOFA, 0.87 for SAPS II, 0.93 for model 1, 0.92 for model 2, and 0.90 for model 3 (Figure 1 ). Comparison of the AUROCs of the 3 general scoring systems revealed a significant difference in favor of APACHE II vs SOFA (P = .02) and no difference between APACHE II and SAPS II (P = .26) or between SAPS II and SOFA (P = .21). Of note, comparison of the AUROCs between the 3 models produced by the multivariate analysis showed no statistically for aggressive supportive care and the presence of septic shock, cytopenias, and organ failure (Table 4) . During patients' ICU stay, the need for continuation of aggressive supportive treatment (mechanical ventilation, vasopressors, and renal replacement therapy), hematologic abnormalities, and organ dysfunctions were adversely related to ICU survival. Of note, 91% of the 34 patients who required renal replacement therapy died of their illness. (18) 7 (10) 60 (90) 6 (9) 19 (28) 44 (66) 4 (6) 36 (54) 21 (31) 10 (15) 
Multivariate Analysis
Other outcomes
Days of mechanical ventilation, median (25%-75% interquartile range) Days in ICU, median (25%-75% interquartile range) performance; in no comparison was it the least effective prognostic index.
As shown in Table 6 , the evaluation of the goodness-of-fit for all 6 scoring systems showed good calibration (P > .05 for every score). According to the goodness-of-fit findings, models 1, 2, and 3 (P = .65, .44, and .43, respectively) had better calibration than did APACHE II (P = .17), SOFA (P = .22), and SAPS II (P = .14). General scoring systems and model 3 tended to give underestimates of mortality (SMR, >1.0), whereas models 1 and 2 tended to give overestimates of mortality (SMR, <1.0); however, the difference between actual and estimated mortality was not significant for any of these 6 models (Figures 2 and 3) .
Additionally 
Discussion
In this study of cancer patients admitted to the ICU, we found that scores on each of the general scoring systems for severity of illness (APACHE II, SOFA, and SAPS II) calculated on the first day of significant difference (model 1 vs model 2, P = .68; model 1 vs model 3, P = .16; and model 2 vs model 3, P = .42). Finally, the comparison of discrimination between the 3 general and the 3 specific prognostic models revealed no difference between APACHE II and models 1, 2, and 3; a significant difference in favor of models 1, 2, and 3 vs SOFA; a significant difference in favor of models 1 and 3 vs SAPS II; and no difference between SAPS II and model 2. In other words, the APACHE II score was the general prognostic model with the best overall discriminative Table 6 Area Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation; ROC = receiver operating characteristic curve; SAPS = Simplified Acute Physiology Score; SE = standard error; SMR = standardized mortality rate; SOFA = Sepsis-related Organ Failure Assessment; 95% CI = 95% confidence interval.
ICU stay were fairly accurate predictors of ICU mortality, with good discrimination and acceptable calibration. Of interest, combining scores of the generic models SOFA and SAPS II with variables not encompassed by the models, such as a patient's performance status; presence of septic shock, infection, and anemia; and admission from a medical department, resulted in prognostic models with improved calibration and discrimination. Of note, use of the APACHE II score as a stand-alone prognostic predictor was not surpassed by any other scoring system or model in discrimination.
Studies on prognostic models for cancer patients requiring intensive care are often contradictory, depending on case mix, studied parameters, monitored outcomes, and statistical methods of analysis. To the best of our knowledge, our finding that scores on APACHE II, SOFA, and SAPS II and 3 additional models are all acceptable prognostic indicators in the same cohort of cancer patients has not been previously reported. However, in a similar study 29 of 5 general severity-of-illness scores (APACHE II and III-J, SAPS II, Mortality Probability Model 37 at ICU admission and 24 hours later), and 1 specific score, the ICU Cancer Mortality Model (ICM), 38 discrimination was good for all 6 of the studied models, but calibration was uniformly insufficient. Of note, a well-known weakness of the HosmerLemeshow goodness-of-fit tests is that the sample size has a major effect on the measured calibration but does not affect discrimination. 34 This fact can explain the discrepancy between our findings and the results of the study of Soares et al, 29 which included a cohort 10 times larger.
Few investigators have evaluated the performance of both APACHE II and SAPS II in the same population of critically ill cancer patients. Sculier et al 23 found no major difference between the 2 scoring systems, which were the only significant factors for hospital and ICU mortality. Berghmans et al 39 found that the variables predictive of ICU mortality were the ICM and APACHE II scores; SAPS II and cancer type, status, and phase were not statistically significant. ICM and SAPS II values were predictive of hospital mortality; APACHE II scores and cancerrelated variables were not useful. Schellongowski et al 40 reported that the capability of SAPS II to discriminate between survivors and nonsurvivors (AUROC, 0.82) was better than that of APACHE II (AUROC, 0.78). All scores had acceptable calibration, although the statistical significance for the Hosmer-Lemeshow goodness-of-fit tests was marginal. Contrary to these 3 studies and our findings, Massion et al 28 found that APACHE II and SAPS II values had no prognostic value, whereas the difference of the Multiple Organ Dysfunction score between the day of admission and day 5 allowed prediction of hospital mortality. However, this study 28 spanned a 10-year period and the sample consisted solely of patients with hematologic tumors who required intensive care. Thus, the findings 28 may not be directly comparable with the findings of other studies. In our opinion, a correlation between the APACHE II and SAPS II scores should be expected because of the overlap in the included variables.
www.ajcconline.org All severity scores were fairly accurate predictors of ICU mortality.
From a purist's point of view, the SOFA score is a description and measure of organ failure, not a general severity-of-illness score. Nevertheless, some investigators have compared SOFA with SAPS II. For example, in a study of patients with oncohematologic tumors, Lamia et al 41 found similar AUROCs for SAPS II and SOFA scores at day 1, and in a study of similar patients, Cornet et al 25 patients showed that SOFA scores at ICU admission were predictive of outcome.
Even though it seems high, the ICU mortality of our cohort does not differ from mortality reported in other recently published similar studies. 6, 10, 17, 25, 40 An interesting and consistent result of our analysis is that the incorporation, among other variables, of performance status in models 1 to 3 and in APACHE II, SAPS II and SOFA improved their performance, whereas the characteristics of the underlying tumor, such as its status, phase, extent, and type, seemed to bear no influence on ICU mortality. This finding agrees with the results of other studies 23, 24 and suggests that the medical decision to admit a cancer patient to the ICU should not be influenced by the characteristics of the tumor but by the physiological derangements and the patient's level of functioning before the admission to the ICU.
Our study had several limitations. First, the relatively small sample size and the use of only 2 ICUs with specific admission and discharge policies, treatment strategies, and patterns of end-of-life decisions may limit the generalizability of our findings. Specifically, the small sample size did not allow us to create separate training and test populations. Second, we examined only the general prognostic scores because intensivists are familiar with the use of these scores and routinely calculate them and the cancer-specific model has not had a consistent advantage over the general models. 29 Third, we included only 1 bone marrow transplant patient, and we cannot make any inference about this specific subgroup of patients. Finally, we did not collect data on cost, long-term outcomes, and the burden placed by the ICU stay on patients' families; these parameters may strongly influence physicians' decisions in the future.
Even though in our cohort of cancer patients the general prognostic scores as well as the expanded models had adequate performance, the overall accuracy was approximately 80%. This finding means that 1 of 5 can cer patients would be at risk of misclassification if admission decisions were made on the sole basis of these predictors. Therefore, the prognostic scores are best used to estimate the probability of mortality for groups of patients, not for individual patients. On the other hand, basing decision making exclusively on clinical judgment is too vague and may prove equally misleading. In a recent 1-year hospital-wide study 42 of all cancer patients for whom admission to the ICU was requested but not performed because they were considered "too well" or "too sick" to benefit, the 30-day mortality rates were 21.3% and 74%, respectively.
Conclusion
The search for universally useful prediction models is likely to be unsuccessful because no prognostic factor or combination of parameters is unequivocally predictive of outcome. In addition, the models already in use are representative of only the populations in which they were developed and do not take into consideration parameters such as ICU economic aspects and nurse to patient ratios. However, we think that ICU practitioners should have a basic understanding of the merits and drawbacks of these tools. Moreover, ICU staff should periodically assess the predictive performance of the tools and adjust the instruments to the unit's practices via customization. 43 Finally, even though the outcome prediction models are not perfect preadmission screening tools, they can be used for benchmarking and can help intensivists inform patients and patients' relatives about prognosis.
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